Comparison of dengue virus and HCV: From impact on global health to their RNA-dependent RNA polymerases

Future Virology

Volumn 9, Issue 1, 2014, Pages 53-67

  Potisopon, Supanee ^a   Priet, Stéphane ^a   Selisko, Barbara ^a   Canard, Bruno ^a  

^a Centre National de la Recherche Scientifique   (France)

Author keywords

antiviral drug development; dengue virus; Flaviviridae; flaviviruses; hepatitis C virus; plus strand RNA viruses; protein structure; RNA replication; RNA dependent RNA polymerases

Indexed keywords

EID: 84893864367     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.121     Document Type: Review

References (84)

1. Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Fields Virology. Knipe D, Howly P. Lippincott-Raven Publishers, PA, USA, 1155-1227 (2007).
2. Fernandez-Garcia M-D, Mazzon M, Jacobs M, Amara A. Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 5, 318-328 (2009).
3. Heinz FX, Stiasny K. Flaviviruses and their antigenic structure. J. Clin. Virol. 55, 289-295 (2012).
4. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 300, 960-962 (2008).
5. Dengue Viruses. Nature Education (2013). www.nature.com/scitable/ topicpage/dengue-viruses-22400925
6. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21st century. Trop. Med. Heal. 39, 3-11 (2011).
7. WHO. Dengue: guidelines for diagnosis, treatment, prevention and control. WHO Press, Switzerland (2009).
8. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 496, 504-507 (2013).
9. Schaffner F, Medlock JM, Van Bortel W. Public health significance of invasive mosquitoes in Europe. J. Clin. Virol. 19, 685-692 (2013).
10. Rochlin I, Ninivaggi DV, Hutchinson ML, Farajollahi A. Climate change and range expansion of the Asian tiger mosquito (Aedes albopictus) in northeastern USA: implications for public health practitioners. PLoS ONE 8, e60874 (2013).
11. Ruche G, Souarès Y, Armengaud A, et al. First two autochthonous dengue virus infections in metropolitan France, September 2010. Euro Surveill. 15, 19676 (2010).
12. Gjenero-Margan I, Aleraj B, Krajcar D, et al. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill. 16, 19805 (2011).
13. Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J. Clin. Virol. 39, 76-81 (2007). (Pubitemid 46777437)
14. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 30, 4301-4306 (2012).
15. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch. Virol. 158, 1445-1459 (2013).
16. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled Phase 2b trial. Lancet 380, 1559-1567 (2012).
17. Halstead SB. Dengue vaccine development: a 75% solution? Lancet 380, 1535-1536 (2012)
18. Tricou V, Vu HTT, Quynh NVN, et al. Comparison of two dengue NS1 rapid tests for sensitivity, specificity and relationship to viraemia and antibody responses. BMC Infect. Dis. 10, 142 (2010).
19. Moi ML, Omatsu T, Tajima S, et al. Detection of dengue virus nonstructural protein 1 (NS1) by using ELISA as a useful laboratory diagnostic method for dengue virus infection of international travelers. J. Travel. Med. 20, 185-193 (2013).
20. Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Neglected. Trop. Dis. 5, e1309 (2011).
21. Murray KO, Rodriguez LF, Herrington E, et al. Identification of dengue fever cases in Houston, Texas, with evidence of autochthonous transmission between 2003 and 2005. Vector Borne Zoonotic Dis. 13(12), 835-845 (2013).
22. Allard PM, Dau ET, Eydoux C, et al. Alkylated flavanones from the bark of Cryptocarya chartacea as dengue virus NS5 polymerase inhibitors. J. Nat. Prod. 74, 2446-2453 (2011).
23. Allard PM, Leyssen P, Martin MT, et al. Antiviral chlorinated daphnane diterpenoid orthoesters from the bark and wood of Trigonostemon cherrieri. Phytochemistry 84, 160-168 (2012).
24. Coulerie P, Eydoux C, Hnawia E, et al. Biflavonoids of Dacrydium balansae with potent inhibitory activity on dengue 2 NS5 polymerase. Planta Med. 78, 672-677 (2012).
25. Noble CG, Lim SP, Chen Y-L, et al. Conformational flexibility of the dengue virus RNA-dependent RNA polymerase revealed by a complex with an inhibitor. J. Virol. 87, 5291-5295 (2013).
26. Latour DR, Jekle A, Javanbakht H, et al. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7- deazaadenosine triphosphate. Antiviral Res. 87, 213-222 (2010).
27. Niyomrattanakit P, Chen YL, Dong H, et al. Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J. Virol. 84, 5678-5686 (2010).
28. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989). (Pubitemid 19117877)
29. WHO. Hepatitis C (2013). www.who.int/mediacentre/factsheets/fs164/en.
30. Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best Pract. Res. Clin. Gastroentrol. 17, 259-275 (2003).
31. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes, updated criteria and assignment web resource. Hepatology doi:10.1002/hep.26744 (2013) (Epub ahead of print).
32. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973 (2005). (Pubitemid 41401136)
33. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM. Lippincott-Raven Publishers, PA, USA, 1101-1151 (2007).
34. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin. Biol. Ther. 13, 1109-1124 (2013).
35. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967-972 (2005). (Pubitemid 41191673)
36. Paeshuyse J, Dallmeier K, Neyts J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr. Opin. Struct. Biol. 1, 590-598 (2011).
37. Clark V, Nelson DR. The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C. Liver Int. 32(Suppl. 1), 103-107 (2012).
38. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl. 1), i36-i46 (2012).
39. Bühler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int. 32(Suppl. 1), 9-16 (2012)
40. Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trial. Gastroenterology doi:10.1053/j. gastro.2013.10.058 (2013) (Epub ahead of print).
41. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368, 34-44 (2013).
42. Dong H, Zhang B, Shi PY. Flavivirus methyltransferase: a novel antiviral target. Antivir. Res. 80, 1-10 (2008).
43. 43 Ferron F, Decroly E, Selisko B, Canard B. The viral RNA capping machinery as a target for antiviral drugs. Antivir. Res. 96, 21-31 (2012).
44. 44 Fang S, Wu Y, Wu N, Zhang J, An J. Recent advances in DENV receptors. Sci. World J. 2013, 684690-68496 (2013).
45. 45 Backovic M, Rey FA. Virus entry: old viruses, new receptors. Curr. Opin. Virol. 2, 4-13 (2012).
46. 46 Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44, 527-535 (2006). (Pubitemid 44433708)
47. 47 von Hahn T, Rice CM. Hepatitis C virus entry. J. Biol. Chem. 283, 3689-3693 (2008).
48. 48 Shi Q, Jiang J, Luo G. Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes. J. Virol. 87, 6866-6875 (2013).
49. Nagy PD, Pogany J. The dependence of viral RNA replication on co-opted host factors. Nat. Rev. Microbiol. 10, 137-149 (2012).
50. Welsch S, Miller S, Romero-Brey I, et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 5, 365-375 (2009).
51. Romero-Brey I, Merz A, Chiramel A, et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 8, e1003056 (2012).
52. Lemon SM, Walker C, Alter MJ, Yi M. Hepatitis C virus. In: Fields Virology. Knipe DM, Howley PM. Lippincott-Raven Publishers, PA, USA, 1253-1304 (2007).
53. Bressanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13039 (1999).
54. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6, 937-943 (1999). (Pubitemid 29463307)
55. Scrima N, Caillet-Saguy C, Ventura M, Harrus D, Astier-Gin T, Bressanelli S. Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. J. Virol. 86, 7107-7117 (2012).
56. Biswal BK, Cherney MM, Wang M, et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005). (Pubitemid 41389065)
57. Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb-and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80, 6146-6154 (2006). (Pubitemid 43849192)
58. Bollati M, Alvarez K, Assenberg R, et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antivir. Res. 87, 125-148 (2010).
59. Issur M, Geiss BJ, Bougie I, et al. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 15, 2340-2350 (2009).
60. Latour DR, Jekle A, Javanbakht H, et al. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7- deazaadenosine triphosphate. Antiviral Res. 87, 213-222 (2010).
61. Filomatori CV, Iglesias NG, Villordo SM, Alvarez DE, Gamarnik AV. RNA sequences and structures required for the recruitment and activity of the dengue virus polymerase. J. Biol. Chem. 286, 6929-6939 (2011).
62. Selisko B, Dutartre H, Guillemot J-C, et al. Comparative mechanistic studies of de novo RNA synthesis by flavivirus RNA-dependent RNA polymerases. Virology 351, 145-158 (2006). (Pubitemid 44056063)
63. Selisko B, Potisopon S, Agred R, et al. Molecular basis for nucleotide conservation at the ends of the dengue virus genome. PLoS Pathog. 8, e1002912 (2012).
64. Yap TL, Xu T, Chen Y-L, et al. Crystal structure of the dengue virus RNAdependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J. Virol. 81, 4753-4765 (2007) (Pubitemid 46668672)
65. Malet H, Egloff M-P, Selisko B, et al. Crystal structure of the RNA polymerase domain of the West Nile virus nonstructural protein 5. J. Biol. Chem. 282, 10678-10689 (2007). (Pubitemid 47093413)
66. Ferrer-Orta C, Arias A, Escarmis C, Verdaguer N. A comparison of viral RNA-dependent RNA polymerases. Curr. Opin. Struct. Biol. 16, 27-34 (2006). (Pubitemid 43221868)
67. Choi KH. Viral polymerases. Adv. Exp. Med. Biol. 726, 267-304 (2012).
68. Andreeva A, Howorth D, Chandonia J-M, et al. Data growth and its impact on the SCOP database: new developments. Nucleic Acid Res. 36, D419-D425 (2008). (Pubitemid 351149760)
69. Mosley RT, Edwards TE, Murakami E, et al. Structure of hepatitis C virus polymerase in complex with primerlate RNA. J. Virol. 86, 6503-6511 (2012).
70. Noble CG, Shi P-Y. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antivir. Res. 96, 115-126 (2012).
71. Harrus D, Ahmed-El-Sayed N, Simister PC, et al. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem. 285, 32906-32918 (2010).
72. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 8, 3867-3874 (1989). (Pubitemid 20016069)
73. Castro C, Smidansky ED, Arnold JJ, et al. Nucleic acid polymerases use a general acid for nucleotidyl transfer. Nat. Struct. Mol. Biol. 16, 212-218 (2009).
74. Yang X, Smidansky ED, Maksimchuk KR, et al. Motif D of viral RNA-dependent RNA polymerases determines efficiency and fidelity of nucleotide addition. Structure 20, 1519-1527 (2012).
75. Gong P, Peersen OB. Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc. Natl Acad. Sci. USA 107, 22505-22510 (2010).
76. Bruenn JA. A structural and primary sequence comparison of the viral RNAdependent RNA polymerases. Nucleic Acid Res. 31, 1821-1829 (2003). (Pubitemid 36432688)
77. Choi KH, Rossmann MG. RNA-dependent RNA polymerases from Flaviviridae. Curr. Opin. Struct. Biol. 19, 746-751 (2009).
78. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76, 3482-3492 (2002). (Pubitemid 34224549)
79. Gorbalenya AE, Pringle FM, Zeddam J, et al. The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J. Mol. Biol. 324, 47-62 (2002). (Pubitemid 35352179)
80. Ferrer-Orta C, Arias A, Perez-Luque R, Escarmís C, Domingo E, Verdaguer N. Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J. Biol. Chem. 279, 47212-47221 (2004).
81. Caillet-Saguy C, Simister PC, Bressanelli S. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J. Mol. Biol. 414, 370-384 (2011).
82. Butcher SJ, Grimes JM, Makeyev EV, Bamford DH, Stuart DI. A mechanism for initiating RNA-dependent RNA polymerization. Nature 410, 235-240 (2001). (Pubitemid 32216599)
83. Hong Z, Cameron CE, Walker MP, et al. A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285, 6-11 (2001). (Pubitemid 32589002)
84. Lu G, Gong P. Crystal structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathog. 9, e1003549 (2013).